VG Life Sciences Inc.

Equities

VGLS

US91822T1016

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:38:12 2024-04-29 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	+9,900.00%

2018	Feelux Co., Ltd completed the acquisition of 23.09% stake in VG Life Sciences Inc. from Alpha Holdings, Inc. and others for KRW 17.3 billion.	CI
2017	Alpha Holdings, Inc. cancelled an additional stake of 12.49% in VG Life Sciences Inc from TJU Asset Management, LLC and Penn Life Science, LLC.	CI

Viral Genetics Inc. will Change its Name to VG Life Sciences Inc

November 27, 2012 at 12:00 am EST

Effective November 27, 2012, Viral Genetics Inc. will change its name to VG Life Sciences Inc.

Latest news about VG Life Sciences Inc.

Feelux Co., Ltd completed the acquisition of 23.09% stake in VG Life Sciences Inc. from Alpha Holdings, Inc. and others for KRW 17.3 billion.	18-11-22	CI
Alpha Holdings, Inc. cancelled an additional stake of 12.49% in VG Life Sciences Inc from TJU Asset Management, LLC and Penn Life Science, LLC.	17-10-11	CI
VG Life Sciences Inc. announced that it has received $5.226 million in funding from Alpha Holdings, Inc.	16-10-30	CI
Alpha Holdings, Inc. agreed to acquire an additional stake of 12.49% in VG Life Sciences Inc from TJU Asset Management, LLC and Penn Life Science, LLC for KRW 4.7 billion.	16-10-11	CI
VG Life Sciences Inc. announced that it expects to receive $5.23 million in funding from Alpha Holdings, Inc.	16-09-11	CI
VG Life Sciences Inc. Announces Management Changes, Effective April 1, 2016	16-03-30	CI
VG Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	15-04-14	CI
VG Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	15-02-10	CI
VG Life Sciences Inc. Progress Update Phase I Cancer Study	14-09-04	CI
VG Life Sciences Inc. Reports Clinical Outcomes in Phase I Cancer Study	14-03-14	CI
VG Life Sciences, Inc. Announces Update on Phase I Cancer Study	13-12-13	CI
VG Life Sciences Inc. Closes $2,235,000 from Private Fund	13-10-02	CI
VG Life Sciences Inc. announced that it has received $2.24 million in funding.	13-10-02	CI
Vg Life Sciences, Inc. Names John Tynan as Interim CEO & President	13-07-18	CI
VG Life Sciences Inc. Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial	13-04-04	CI
VG Life Sciences Inc. Signs Two-Year Commitment to Provide Funding Toward the Operational Needs from MedBridge, LLC; to Appoint David Odell as Board of Director	13-03-22	CI
VG Life Sciences Inc. announced that it has received $0.05 million in funding	13-03-21	CI
VG Life Sciences Inc. Completes First Stage of its Phase I Trial to Treat Ovarian Cancer	13-01-31	CI
VG Life Sciences Inc. Expands Ovarian Cancer Trial	13-01-14	CI
VG Life Sciences Inc. has Changed its Ticker to VGLS from VRAL	13-01-10	CI
Viral Genetics Inc. will Change its Name to VG Life Sciences Inc	12-11-27	CI
Viral Genetics Inc. Submits Pre-IND Document for Lyme Disease Drug Candidate to United States Food and Drug Administration	12-03-07	CI
Viral Genetics Inc. Adds Nathan Tinker to Corporate Development Advisory Board	12-02-28	CI

Chart VG Life Sciences Inc.

Duration

Period

More charts

Company Profile

VG Life Sciences Inc. is engaged in research and development of therapeutic and diagnostic pharmaceutical and medical products. The Company has not generated any revenue.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VG LIFE SCIENCES INC.	+9,900.00%	2.11M
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+47.70%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research